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Endocrine Therapy for Prostatic Cancer 
Can Replace Orchiectomy and Estrogens 
By treating patients who have advanced prostate cancer with 
a drug that changes endocrine function, physicians in the UT 
MDAH Department of Urology have produced remissions and 
promoted well-being in patients who have traditionally had to 
face the radical side effects of surgical castration and estrogen 
therapy. 
Since January 1983, Andrew C. von Eschenbach, M.D., 
department chairman, has led a study of the use of buserelin, 
a luteinizing hormone-releasing hormone (LHRH) agonist, in 
22 men between the ages of 59 and 80. All had stage D prostate 
cancer that had metastasized. 
Tests to establish tumor stage and identify metastasis 
included biopsy, hematologic and biochemical blood assays, 
urinalysis, radionuclide bone scan, bone radiographs , and 
lymphangiography or computed tomography (CT) scan, or both. 
The patients' general physical condition and endocrine 
function were evaluated at the beginning and during therapy. 
Clinical monitoring in collaboration with Naguib A. Samaan, 
M.D., Department of Endocrinology, and Herbert A. Fritsche, 
Ph.D., Department of Laboratory Medicine, continues for 
patients who are still taking buserelin, although entry into the 
formal study period has ended. 
Buserelin has not yet been approved by the Food and Drug 
Administration for general clinical use, but a similar drug, 
luprolide (Lupron), is now on the market after being tested at 
other resesearch centers. It is prescribed by MDAH physicians 
for some patients with prostate cancer who are not in the 
buserelin study. 
During the first week of therapy, the patients received 1,500 µg 
of buserelin daily, administered subcutaneously in three doses 
of 500 µg each, after which the daily dose has been 200 µg. 
In a recent interview, von Eschenbach described the results 
of the study. "Buserelin treatment resulted in a favorable 
response in all 22 patients," he said. "Nineteen patients had 
bone scans that were considered positive for metastatic disease, 
and 13 of these patients demonstrated improvement. Thirteen 
patients had lymph node metastases, which regressed in eight 
patients. Among 17 patients who showed abnormal prostatic 
acid phosphatase (PAP) secretion, 15 patients improved, and 
in 12 of these the PAP levels returned to normal." 
Today, nine patients are still in the study. The others suffered 
relapses and are being treated with chemotherapy. Six patients 
have died, including two who died from causes other than 
prostate cancer. 
Endocrine therapy, von Eschenbach said, is not curative, nor 
is any other therapy so far attempted for patients in advanced 
stages of the disease. But endocrine therapy promotes remis-
sions. It usually alleviates the severe pain of disseminated prostat-
ic cancer in the bones and may relieve problems of urination 
caused by urethral obstruction, thus improving the patients' per-
formance status and emotional well-being. 
The major advantage of this kind of endocrine therapy, von 
Eschenbach said, is that buserelin and similar drugs have made 
orchiectomy and estrogen therapy-which caused gynecomastia 
in most patients-no longer obligatory. The problems of loss 
of libido and impotence remain, because all endocrine treat-
ments for prostate cancer exert their effects by withdrawing 
testosterone from these hormone-sensitive tumors (Fig. I). 
Most Prevalent Cancer in Men 
The buserelin results have an importance beyond their num-
bers, von Eschenbach explained, because cancer of the prostate 
is an example of the diagnostic and treatment problems clini-
cians face in dealing with many other forms of neoplasia. 
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Fig. 1. Mechanisms of endocrine regulation. The prostate is 
directly affected by androgens produced principally by the tes-
tis. These various regulatory mechanisms provide numerous 
options for endocrine control strategies. ACTH, adrenocor-
ticotropic hormone; FSH, follicle-stimulating hormone; LH, lu-
teinizing hormone. (Reproduced with permission from Smith, 
D. R.: General Urology, 11th Ed. Copyright 1984 by Lange 
Medical Publications, Los Altos, CA.) 
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Although it is a disease of aging and rarely occurs in men 
younger than 50, it is one of the most common cancers in men. 
About 75,000 cases of prostate cancer are expected to be diag-
nosed annually, and about 24,000 deaths occur yearly as a result 
of the disease. 
Prostate cancers have differing biologic characteristics and 
malignant potential, ranging from the slow-growing, confined 
tumor to the type that grows rapidly and quickly develops 
aggressive metastasis. In the mid-range is the prostatic tumor 
that grows slowly for years and then suddenly develops suffi-
cient numbers of cell clones to disseminate to the bones and 
lympathic system. 
The disease was once considered rare because it is so difficult 
to diagnose. Compared to the number of prostate cancers diag-
nosed, three to eight times more cases are not found until 
patients undergo a prostatectomy for benign disease or during 
autopsy examinations. 
A comparable disease is breast cancer in women, but this 
occurs earlier in life and is perhaps easier to diagnose at earlier 
stages because of public and medical education about the dis-
ease. There are striking similarities between breaat and prostate 
cancer; for example, both are adenocarcinomas for which hor-
monal treatments are used, von Eschenbach said. 
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Because of the difficulties of diagnosing prostatic carcinoma 
and the heterogeneity of its expression, von Eschenbach and 
his colleagues have called for a new look at the incidence, 
development, diagnosis, therapeutic decisions, and evaluat ion 
of results-a new effort of which the buserelin study is a part. 
Epidemiologic Factors 
Epidemiologic studies have shown, he said, that genetic 
factors (Fig. 2) may play a role because cancer of the prostate 
is more common among American black men than white men, 
and because Oriental peoples in their home countries have a 
lower incidence of clinically diagnosed disease. The latter find-
ing has also led to the suggestion that a diet low in fat and rich 
in vitamins A and D may play a part in modulating the inci-
dence and virulence·of malignant prostatic disease. Environ-
mental factors may have an influence as well, since some studies 
have linked work in the rubber, textile, and fert ilizer industries 
to higher rates of prostate cancer. 
That hormones have a role is certain, although their exact 
mechanism of action is not known and the responsible endo-
crine factors have not been identified. The appearance of 
prostate cancer after age 50 suggests strongly, however, that 
development of the cancer is related to changes with age in 
the male endocrinologic environment, when serum testoster-
one declines and the ratio of estrogen to testosterone rises. The 
fact that prostatic carcinoma responds to androgen deprivation 
supports a direct relationship between the tumor and hormonal 
change. 
Pathologic Features 
As von Eschenbach explained, the formation of malignant 
tissue begins in the stem cells of the acinar prostatic epitheli-










Fig. 2. Epidemiologic influences. Many factors may contribute 
to the development of cancer of the prostate and affect its 
biologic behavior. (Reproduced with permission from von 
Eschenbach, A. C.: Cancer of the prostate, in Hickey, R. c. 
et al., eds.: Current Problems in Cancer. Copyright 1981 by 
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Fig. 3. St aging of prostate cancer . Based on extent of tumor, 
various modifications in the A, B, C, and D types of prostate 
cancer have been proposed and are currently in use, but the 
definition of t hese subdivisions is not uniform. (Reproduced 
with permission from von Eschenbach, A. C.: Cancer of the 
prostate, in Hickey, R. C. et al., eds.: Current Problems in 
Cancer. Copyright 1981 by Year Book Medical Publishers, 
Chicago.) 
continued from page 2 
um. The degree of abnormality varies, so that some tumors are 
difficult to distinguish from normal prostate tissue, except that 
the glands are small and crowded. In others the cellular struc-
ture will be strikingly altered, with the tissue forming a solid 
pattern in which the glands cannot be distinguished. Since struc-
tural differences may occur in parts of the same tumor, the grad-
ing of prostate cancer is often difficult and confusing. 
Fig. 3 is a graphic interpretation of tumor stages. At this hos-
pital, von Eschenbach explained, stage is based on extent of dis-
ease, and tumor grade is based on percentage of gland forma-
tion within the primary tumor. 
Clinical Findings 
The tumor has few warning signs because it does not progress 
in predictable fashion from microscopic disease to regional 
spread to distant metastasis. That is why, in many patients, 
symptoms of metastasis may occur before the disease is diag-
nosed in the prostate gland. Benign disease usually causes 
obstructive voiding symptoms in older men. Prostate cancer, 
however, originates in the periphery of the gland and impairs 
micturition only after the tumor has grown quite large. Most 
patients do not experience pain on ejaculation or have problems 
of sexual function but, according to von Eschenbach, 
hematospermia and hematuria, which may accompany benign 
hypertrophic hyperplasia, may lead to the detection of 
unsuspected cancer. The presence of these symptoms in patients 
older than 50 years should always alert physicians to do a 
careful assessment . 
This is true also for elderly men who may complain of persis-
tent bone pain, which may be multifocal or restricted to the 
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Fig. 4. Trilogy of the clinical manifestations of prostate cancer. 
(Reproduced with permission from Johnson, D. E., and von 
Eschenbach, A. C.: Prostatic carcinoma: A trilogy of clinical 
expressions. Southern Medical Journal 73( 10): 1304, 1980.) 
spine or pelvis. A general feeling of illness, fatigue, and weight 
loss are nonspecific clinical indications of the disease. 
Fig. 4 represents the clinical manifestations, which von Eschen-
bach summarized as follows: 
• Changes in the size, shape, or consistency of the prostate. 
A hard discrete nodule in the prostate of a man older than 
50 has an about 50% chance of being a malignant tumor. 
• Metastases to the bones manifested by areas of tenderness 
on palpation. Sometimes lymphadenopathy is detected by 
palpating the inguinal region, the pelvic side wall, or the 
supraclavicular fossa. 
When a patient is suspected of having cancer of the prostate, 
von Eschenbach recommended these procedures: 
• Biopsy of the gland with histologic examination of tissue 
obtained by needle biopsy of the prostate or, at times, by 
transurethral resection. 
• Laboratory studies including complete blood count :3-nd 
serum biochemical profile. Determination of the serum level 
of acid phosphatase is most important because of the 
association of elevated levels of serum acid phosphatase and 
advanced prostatic cancer. 
• Radiologic studies including chest radiography, radiographs 
of the lower spine and pelvis, and radionuclide bone scan. 
• Lymphangiography for patients suspected of having nodal 
disease . 
• CT complementary to lymphangiography. Although CT 
scans do not show intranodal architecture, they reveal 
enlarged nodes completely replaced by the tumor. Unfor-
tunately, both CT scans and lymphangiograms tend to 
understage patients with nodal disease. 
continued on page 4 
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Fig. 5. Decision matrix for selecting therapy. Tumor grade is 
correlated with increasing malignant potential, and tumor stage 
is correlated with increasing tumor burden. TURP, transurethral 
resection of the prostate. (Reproduced with permission from 
Smith, D. R.: General Urology, 11th Ed. Copyright 1984 by 
Lange Medical Publications, Los Altos, CA.) 
Treatment 
Dr. von Eschenbach summarized treatment, according to the 
stages of prostatic cancer, as transurethral resection of the 
prostate; radical prostatectomy; interstitial radiation, external-
beam megavoltage radiation, or a combination of the two; 
endocrine therapy; and chemotherapy (Fig. 5). 
He has emphasized endocrine therapy because about one-third 
of patients already have clinical evidence of metastasis at the 
time of diagnosis, when total eradication is impossible by 
currently available techniques. 
"Charles Huggins won the Nobel Prize in 1966," he said, "for 
his discovery in the 1940s of the hormonal mechanisms of 
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Andrew C. von Eschenbach and research nurse Lydia Madsen. 
prostate cancer, and his work is still the basis of our endocrine 
treatment. But we are now learning that we can substitute new 
drugs for the castration and estrogen therapy that can have such 
severe physical and emotional consequences. 
"The di ease is so common, yet so often hidden for years , 
that we must find methods of earlier diagnosis, and more effec-
tive treatment for cure. To accomplish this we must learn more 
about this tumor'~ biology and behavior." ~ 
(Physicians who desire additional information may write Andrew 
C. von Eschenbach, M .D., Department of Urology , MDAH 
Box 110, The University of Texas M. D. Anderson Hospital and 
Tumor Institute, 6723 Bertner Avenue, Houston, Texas 
77030-ED.) 
The Cancer Information Service provides up-to-date infor-
mation and literature about cancer via toll-free telephone lines. 
Patients can reach CIS at: 
1-800-4-CANCER toll-free in Texas 
and 792-3245 in Houston 
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